Circulating inflammatory and hemostatic biomarkers are associated with risk of myocardial infarction and coronary death, but not angina pectoris, in older men

S. G. WANNAMETHEE,* P. H. WHINCUP,† A. G. SHAPER,* A. RUMLEY,‡ L. LENNON* and G. D. O. LOWE‡

*Department of Primary Care and Population Health, UCL Medical School, Royal Free Campus, London; †Division of Community Health Sciences, St George’s University of London, London; and ‡Division of Cardiovascular and Medical Sciences, University of Glasgow, Glasgow, UK

To cite this article: Wannamethee SG, Whincup PH, Shaper AG, Rumley A, Lennon L, Lowe GDO. Circulating inflammatory and hemostatic biomarkers are associated with risk of myocardial infarction and coronary death, but not angina pectoris, in older men. J Thromb Haemost 2009; 7: 1605–11.

Summary. Aims: The extent to which hemostatic and inflammatory biomarkers are related to angina pectoris as compared with myocardial infarction (MI) remains uncertain. We examined the relationship between a wide range of inflammatory and hemostatic biomarkers, including markers of activated coagulation, fibrinolysis and endothelial dysfunction and viscosity, with incident myocardial infarction (MI) or coronary heart disease (CHD) death and incident angina pectoris uncomplicated by MI or CHD death in older men. Methods: A prospective study of 3217 men aged 60–79 years with no baseline CHD (angina or MI) and who were not on warfarin, followed up for 7 years during which there were 198 MI/CHD death cases and 220 incident uncomplicated angina cases. Results: Inflammatory biomarkers [C-reactive protein (CRP), interleukin-6, fibrinogen], plasma viscosity and hemostatic biomarkers [von Willebrand factor (VWF) and fibrin D-dimer] were associated with a significant increased risk of MI/CHD death but not with uncomplicated angina even after adjustment for age and conventional risk factors. Adjustment for CRP attenuated the relationships between VWF, fibrin D-dimer and plasma viscosity with MI/CHD death. Comparisons of differing associations with risk of MI/CHD deaths and uncomplicated angina were significant for the inflammatory markers \(P = 0.05\) and marginally significant for fibrin D-dimer \(P = 0.05\). In contrast, established risk factors including blood pressure and high-density lipoprotein (HDL)-cholesterol were associated with both MI/CHD death and uncomplicated angina. Conclusion: Circulating biomarkers of inflammation and hemostasis are associated with incident MI/CHD death but not incident angina uncomplicated by MI or CHD death in older men.

Keywords: angina pectoris, coronary heart disease, hemostasis, inflammation, myocardial infarction.

Introduction

It is well established that inflammation plays a major role in the development and progression of atherosclerosis, including plaque rupture which initiates coronary thrombosis and myocardial infarction (MI) [1]. Activated coagulation, endothelial dysfunction and fibrinolysis have also been associated with risk of coronary heart disease (CHD) [2–13]. The term CHD covers all forms of atherosclerotic disease of the coronary arteries with MI/coronary death as the most serious manifestation and with angina (unstable or stable) as a specific symptom complex indicating myocardial ischemia. Many persons develop only stable angina, with chest pain consistently related to physical exertion or emotional stress. Many prospective studies have shown independent associations between CHD events (MI and CHD death) and C-reactive protein (CRP), interleukin-6 (IL-6), fibrinogen, von Willebrand factor (VWF), fibrin D-dimer and tissue plasminogen activator antigen (t-PA) in both middle-aged and older populations [2–13]. In contrast, information on the association of these circulating biomarkers with the risk of uncomplicated angina events is limited.

The major pathophysiological difference distinguishing MI and other acute coronary syndromes from uncomplicated stable angina pectoris is the rupture of an atherosclerotic plaque with subsequent thrombosis formation which causes...
acute coronary events [1,14]. Some studies (mainly observational in nature) have addressed the question of whether the biological profile of those who develop MI/coronary death may be different from those who have uncomplicated angina [15–19]. Conventional CHD risk factors such as blood lipids, blood pressure and smoking have been shown to predict both MI and angina [20,21]. Few prospective studies have examined whether the relationships of inflammatory and hemostatic biomarkers to angina and MI differ but there is suggestion that many of these factors related to MI including inflammatory markers, endothelial dysfunction and fibrinolytic activity are not related to angina [8–10]. However, in a recent nested case–control study of middle-aged men (PRIME Study) inflammatory but not hemostatic factors predicted stable angina [11]. Whether these findings apply to older men is not known. We hypothesized that the relationship between inflammatory and hemostatic biomarkers including CRP, IL-6 plasma viscosity and several markers of activated coagulation, fibrinolysis and endothelial dysfunction [fibrinogen; coagulation factors VII, VIII, and IX; fibrin D-dimer, t-PA antigen, VWF activated partial thromboplastin time (APTT) and activated protein C (APC) ratio] differed between older men aged 60–79 years who develop (i) incident MI or CHD death and (ii) incident stable angina, uncomplicated by MI or CHD death.

Subjects and methods

The British Regional Heart Study is a prospecvie study of cardiovascular disease involving 7735 men aged 40–59 years drawn from general practice in each of 24 British towns, who were screened between 1978 and 1980 [22]. The population studied was socio-economically representative of British men but consisted almost entirely of white Europeans (> 99%). In 1998–2000, all surviving men, now aged 60–79 years (mean age 68.7 years), were invited for a 20th year follow-up examination. The men completed a questionnaire which included questions on their medical history and lifestyle behavior. They were requested to fast for a minimum of 6 h, during which time they were instructed to drink only water and to attend for measurement at a pre-specified time between 08:00 and 18:00 hours. All men were asked to provide a blood sample, collected using the Sarstedt Monovette system. Four thousand and eighty-eight men had at least two hundred and fifty-two men (77% of survivors) attended for examination. Four thousand and eighty-eight men had at least one hemostatic/inflammatory marker measured. We further excluded men with a recall of a diagnosis of CHD (myocardial infarction or angina) \((n = 793)\) and men on warfarin \((n = 78)\) leaving 3217 men for analysis.

**Cardiovascular risk factors**

Anthropometric measurements including body weight, height and waist circumference (WC) were carried out. Details of measurements and classification methods for smoking status, physical activity, body mass index, WC, social class, blood pressure, high-density lipoprotein (HDL)-cholesterol, triglyce-rides and glucose have been described [23,24]. Men with a doctor diagnosis of diabetes or those with a fasting glucose of \(\geq 7 \text{ mmol L}^{-1}\) (WHO criteria) were considered to have prevalent diabetes.

**Hemostatic and inflammatory biomarkers**

At the 20-year examination, blood was anticoagulated with K$_2$ EDTA (1.5 mg mL$^{-1}$) for measurement of plasma viscosity at 37°C in a semi-automated capillary viscometer (Coulter Electronics, High Wycombe, UK). Blood was also anticoagulated with 0.109 M trisodium citrate (9:1 v:v) for measurement of clottable fibrinogen (Clauss method); as well as coagulation factors (F)VII, VIII and IX; activated partial thromboplastin time (APTT) and activated protein C (APC) ratio (measured by the APTT-based method) in an MDA-180 coagulometer (Orga-non Teknika, Cambridge, UK). Plasma levels of t-PA antitgen and D-dimer were measured with enzyme-linked immunosorbent assays (ELISA) (Biopool AB, Umea, Sweden) as was VWF antigen (Dako, High Wycombe, UK). C-reactive protein (CRP) was assayed by ultra-sensitive nephelometry (Dade Behring, Milton Keynes, UK). IL-6 was assayed using a high-sensitivity ELISA (R&D Systems, Oxford, UK). The inter-assay coefficient of variation (CV) for the biomarkers ranged from < 1% (plasma viscosity) to 8.9% (IL6) and the intra-assay CV ranged from < 1% (plasma viscosity) to 8.4% (APC ratio). Inter- and intra-assay CV for IL-6 was 8.9% and 7.5%, 8.3% and 4.7% for CRP, 3.7% and 2.6% for fibrinogen and 5.2% and 4.7% for fibrin D-dimer.

**Follow-up**

All men have been followed up from initial examination (1978–1980) to June 2006 for all cause mortality and cardiovascular morbidity and follow-up has been achieved for 99% of the cohort [25]. In the present analyses, all morbidity follow-up is based on follow-up from re-screening in 1998–2000 at mean age 60–79 years, a mean follow-up period of 7 years (range 6–8 years). Information on death was collected through the established ‘tagging’ procedures provided by the National Health Service registers. Fatal coronary heart disease events were defined as death with coronary heart disease (ICD codes 410–414) as the underlying code. Evidence regarding non-fatal MI and angina was obtained by reports from general practitioners supplemented by regular 2-yearly reviews of the patients’ practice records (including hospital and clinic correspondence) carried out through to the end of the study period. Diagnosis of a non-fatal MI was confirmed in accordance with World Health Organisation criteria, on the basis of two of the following (i) severe chest pain, (ii) increased levels of cardiac enzymes and (iii) electrocardiography (ECG) changes consistent with MI. Diagnosis of uncomplicated angina refers to the development of chest pain related to exertion or stress, and not superseded by the development of MI or CHD death. Men who developed both angina and MI (or CHD death) \((n = 32)\) were classified as being in the latter group. Thus, the two outcome measures (uncomplicated angina and MI/CHD death) are mutually exclusive.
Statistical methods

Analyses are based on the division of hemostatic and inflammatory markers into equal thirds. Cox’s proportional hazards model was used to assess the multivariate-adjusted relative risk for the highest third compared with the lowest third (reference group). In the adjustment, smoking [never, long term ex-smokers (> 15 years), recent ex-smokers and current smokers], social class (7 groups), physical activity (4 groups), alcohol intake (5 groups), pre-existing diabetes (yes/no) and stroke (yes/no) were fitted as categorical variables. BMI, systolic blood pressure and HDL-C were fitted as continuous variables. Tests for trends were carried out fitting the hemostatic and inflammatory markers in its original continuous form. Differences for associations between the risk factor of interest and MI/CHD deaths and uncomplicated angina were evaluated using likelihood ratio tests based on methods of competing risk survival analysis as described by Glynn and Rosner [26]. The likelihood ratio tests evaluated the hypothesis that the associations of risk factors were the same for MI/CHD deaths and uncomplicated angina. We had 90% power to detect a mean difference of 0.19 in log CRP between men with angina and men with MI.

Results

During the mean follow-up period of 7 years, there were 198 MI or CHD death events and 220 new diagnoses of uncomplicated angina. To evaluate the association between inflammation and CRP, the markers were fitted as categorical variables. BMI, systolic blood pressure and HDL-C were fitted as continuous variables. The statistical significance was assessed using likelihood ratio tests based on methods of competing risk survival analysis as described by Glynn and Rosner [26].

Table 1

| CHD status          | None (n = 2809) | Angina only (n = 220) | P-value for difference | MI/CHD death (n = 198) | P-value for difference |
|---------------------|----------------|----------------------|------------------------|------------------------|------------------------|
| % Current smokers   | 12.5           | 12.6                 | 0.98                   | 21.2                   | 0.0002                 |
| % Physically inactive| 9.1            | 10.7                 | 0.37                   | 13.6                   | 0.07                   |
| % Manual occupation | 52.3           | 54.8                 | 0.46                   | 58.3                   | 0.11                   |
| % Light/moderate drinkers | 40.5   | 42.7                 | 0.57                   | 38.2                   | 0.18                   |
| % Diabetes          | 10.2           | 11.2                 | 0.62                   | 19.2                   | 0.0001                 |
| % Stroke            | 4.1            | 5.6                  | 0.21                   | 6.7                    | 0.21                   |
| Waist circumference (cm) | 96.9   | 97.5                 | 0.57                   | 97.3                   | 0.59                   |
| BMI (kg m⁻²)        | 26.8           | 27.1                 | 0.40                   | 26.9                   | 0.54                   |
| SBP (mmHg)          | 149.6          | 153.3                | 0.02                   | 157.2                  | < 0.0001               |
| Cholesterol (mmol L⁻¹) | 6.06       | 6.21                 | 0.04                   | 6.13                   | 0.32                   |
| HDL-C (mmol L⁻¹)    | 1.35           | 1.26                 | 0.002                  | 1.25                   | < 0.0001               |
| Triglyceride (mmol L⁻¹) | 1.60       | 1.77                 | 0.006                  | 1.73                   | 0.01                   |

Table 2

| Established cardiovascular risk factors and adjusted relative risk (95% CI) of developing angina versus MI/CHD death |
|-------------------------------------------------|-----------------|-----------------|-----------------|
| Angina only                                     | MI/CHD death    |
| Age-adjusted Model 1                           | Age Model 1     |
| Physical inactivity (mod-vig/vig vs. inactive) | 0.98 (0.65, 1.46) | 1.23 (0.80, 1.88) | 0.63 (0.40, 0.99) | 0.80 (0.50, 1.28) |
| Current smoking                                | 1.15 (0.74, 1.78) | 1.02 (0.64, 1.64) | 2.19 (1.46, 3.23) | 1.89 (1.22, 2.91) |
| SBP (mmHg) (T3 vs. T1; ≥ 159.5 vs. < 139.4)    | 1.46 (1.07, 2.01) | 1.43 (1.03, 1.99) | 1.90 (1.32, 2.73) | 1.76 (1.20, 2.57) |
| HDL (mmol L⁻¹) (T3 vs. T1; ≥ 1.5 vs. < 1.2)    | 0.59 (0.22, 0.84) | 0.59 (0.38, 0.93) | 0.52 (0.36, 0.74) | 0.57 (0.39, 0.84) |
| Diabetes                                       | 1.08 (0.72, 1.62) | 0.89 (0.57, 1.40) | 2.10 (1.49, 2.97) | 1.91 (1.32, 2.77) |
| Cholesterol (mmol L⁻¹) (T3 vs. T1; ≥ 6.5 vs. < 5.6) | 1.50 (1.07, 2.10) | 1.73 (1.19, 2.53) | 1.19 (0.85, 1.68) | 1.38 (0.93, 2.04) |
| Triglyceride (mmol L⁻¹) (T3 vs. T1; ≥ 1.96 vs. < 1.28) | 1.30 (0.93, 1.82) | 0.77 (0.50, 1.17) | 1.84 (1.28, 2.63) | 1.32 (0.83, 2.08) |

© 2009 International Society on Thrombosis and Haemostasis
Table 3 Adjusted relative risk (top third vs. bottom third; 95% CI) for angina or MI/CHD death according to levels of inflammatory and hemostatic biomarkers

| Biomarker | Angina only | MI/CHD death |
|-----------|-------------|--------------|
| Unadjusted | Age-adjusted | P-value for linear trend | Unadjusted | Age-adjusted | P-value for linear trend + Adjusted + |
| CRP (≥ 2.54 vs. < 1.0) | 1.07 (0.77, 1.50) | 1.13 (0.81, 1.58) | 0.82 | 2.30 (1.60, 3.29) | 2.04 (1.42, 2.93) | <0.0001 | 1.84 (1.23, 2.77) | 0.002 |
| IL-6 (≥ 2.92 vs. < 1.77) | 0.99 (0.71, 1.37) | 1.06 (0.75, 1.48) | 0.79 | 2.73 (1.89, 3.95) | 2.31 (1.59, 3.36) | <0.0001 | 1.88 (1.26, 2.83) | 0.001 |
| Fibrinogen (≥ 3.44 vs. < 2.93) | 0.97 (0.71, 1.34) | 1.04 (0.75, 1.42) | 0.97 | 2.32 (1.64, 3.28) | 2.05 (1.45, 2.90) | <0.0001 | 1.82 (1.25, 2.63) | 0.004 |
| VWF (≥ 155 vs. < 115) | 0.98 (0.72, 1.33) | 1.06 (0.78, 1.45) | 0.88 | 1.67 (1.19, 2.34) | 1.38 (0.98, 1.95) | 0.0009 | 1.24 (0.87, 1.76) | 0.01 |
| t-PA (≥ 12.1 vs. < 8.7) | 1.05 (0.76, 1.45) | 1.05 (0.76, 1.44) | 0.61 | 1.29 (0.92, 1.82) | 1.19 (0.85, 1.68) | 0.02 | 0.92 (0.62, 1.34) | 0.50 |
| D-dimer (≥ 99 vs. < 56) | 0.88 (0.64, 1.22) | 0.97 (0.69, 1.37) | 0.90 | 2.30 (1.60, 3.31) | 1.74 (1.20, 2.53) | 0.003 | 1.39 (0.94, 2.05) | 0.02 |
| Factor IX (≥ 144 vs. < 122) | 1.20 (0.85, 1.68) | 1.20 (0.86, 1.68) | 0.26 | 1.49 (1.06, 2.11) | 1.48 (1.05, 2.10) | 0.01 | 1.29 (0.89, 1.86) | 0.20 |
| Plasma viscosity (≥ 1.31 vs. < 1.25) | 1.18 (0.85, 1.65) | 1.22 (0.87, 1.71) | 0.17 | 2.53 (1.71, 3.74) | 2.34 (1.58, 3.46) | 0.01 | 1.64 (1.08, 2.49) | 0.03 |

+ Adjusted for age, social class, alcohol intake, BMI, prevalent stroke, smoking, physical activity, diabetes, systolic blood pressure and HDL-C. Test for trend fitting biomarkers in its original continuous form. Missing data: CRP (n = 24); IL6 (n = 37); Fibrinogen (n = 11); VWF (n = 7); t-PA (n = 7); D-dimer (n = 10); Factor IX (n = 9); Plasma viscosity (n = 56). CRP, C-reactive protein; IL-6, interleukin 6; VWF, von Willebrand factor.
Inflammatory and hemostatic markers and CHD

Table 4 Adjusted hazards ratio (95% CI) of MI/CHD death and uncomplicated angina for a standard deviation increase in selected biomarkers

| Biomarker     | MI/CHD death       | Uncomplicated angina |
|---------------|--------------------|----------------------|
|               | Model 1 adjustment | P-trend   | Model 1 + CRP | P-trend | Model 1 adjustment | P-trend |
| SBP           | 1.27 (1.10, 1.47)  | 0.0004    | 1.30 (1.12, 1.50) | 0.0002  | 1.15 (1.00, 1.27)  | 0.04    |
| HDL-C         | 0.79 (0.68, 0.94)  | 0.006     | 0.84 (0.70, 0.99) | 0.04    | 0.76 (0.65)        | 0.008   |
| CRP           | 1.25 (1.09, 1.46)  | 0.002     | –                   | 0.02    | 0.92 (0.79, 1.07)  | 0.27    |
| IL-6          | 1.23 (1.10, 1.46)  | 0.002     | –                   | 0.04    | 0.94 (0.81, 1.10)  | 0.45    |
| Fibrinogen    | 1.21 (1.06, 1.37)  | 0.004     | –                   | 0.04    | 0.91 (0.78, 1.06)  | 0.17    |
| VWF           | 1.19 (1.04, 1.37)  | 0.01      | 1.10 (0.97, 1.30)  | 0.13    | 0.98 (0.83, 1.10)  | 0.80    |
| D-dimer       | 1.18 (1.02, 1.34)  | 0.02      | 1.11 (1.02, 1.31)  | 0.22    | 0.93 (0.80, 1.07)  | 0.34    |
| Plasma viscosity | 1.15 (1.01, 1.30) | 0.03      | 1.05 (0.89, 1.23)  | 0.57    | 1.005 (0.87, 1.16) | 0.93    |

Model 1 adjusted for social class, alcohol intake, BMI, prevalent stroke, smoking, physical activity, diabetes, systolic blood pressure and HDL-Cholesterol. *P-value associated with the null hypothesis that the variable has the same association with MI/CHD death and uncomplicated angina (model 1). P-value obtained by log-likelihood ratio tests. CHD, coronary heart disease; MI, myocardial infarction; VWF, von Willebrand factor.

Discussion

In this prospective study of British men aged 60–79 years without baseline evidence of CHD, we have confirmed the results of previous studies [2–13] that circulating biomarkers of inflammation, endothelial dysfunction, coagulation and fibrinolysis (CRP, IL-6, fibrinogen, plasma viscosity, VWF and fibrin D-dimer) are associated with risk of incident major CHD events (MI or CHD death), after adjustment for traditional CHD risk factors. In contrast, we have also shown that this profile of circulating biomarkers was not associated with risk of new angina pectoris, uncomplicated by MI or CHD death.

Our findings are consistent with limited published evidence from previous cross-sectional [16], case-control [17] and prospective [8–10] studies which have shown no association between inflammatory or hemostatic biomarkers with angina. However, in the recent report from the PRIME Study (a nested case-control prospective study of men aged 40–59 years), inflammatory markers were predictive of both acute coronary syndrome and stable angina but hemostatic markers in particular VWF plasma levels were higher in individuals who subsequently developed MI (fatal or non-fatal) but not in those who develop angina pectoris [11]. The differences in finding between the associations of inflammatory biomarkers and stable angina in the PRIME Study and the present study of older men may relate to the age differences in the two populations. With over 200 cases of incident uncomplicated stable angina, and 200 cases of incident MI/CHD death, among 3200 men followed for a mean of 7 years, the present study significantly and prospectively extends the previous literature comparing the associations of these different CHD outcomes with circulating levels of inflammatory and hemostatic biomarkers.

The evidence from this and previous studies suggests that circulating biomarkers of inflammation [9,16,17], endothelial dysfunction, coagulation and fibrinolysis [8,10,15,17] may be specifically related to acute plaque rupture and thrombosis (the pathophysiological basis of MI and CHD death) [1,14] rather than to slowly progressive occlusive coronary atherosclerosis which (sometimes with coronary artery spasm) is the pathophysiological substrate of uncomplicated stable angina. This suggestion is consistent with evidence that suppression of inflammation [27,28], coagulation [29] and thrombolysis [30] each plays a key role in treatment of acute coronary artery syndromes after plaque rupture. Such processes may potentially be less important in development of uncomplicated stable angina (or, in the arteries supplying the lower limb, uncomplicated intermittent claudication). Nevertheless, the observations in prospective studies that levels of several of these circulating biomarkers predict progressive atherosclerosis in the lower limb [31] suggest that these processes also contribute to progression of chronic arterial occlusion. The associations between VWF, fibrin D-dimer or plasma viscosity with MI/CHD deaths were attenuated after adjustment for CRP, suggesting that the relationship between these variables and CHD may reflect their association with the inflammatory response. No independent associations of coagulation factors (other than fibrinogen), APTT or APC ratio were observed with major CHD events.

Some conventional risk factors including systolic blood pressure and HDL-cholesterol were important risk factors for both MI/CHD death and angina in the present study, which is consistent with previous reports [20,21]. In contrast, cigarette smoking, prevalent diabetes and physical inactivity were only associated with MI/CHD death in this cohort of older men consistent with findings reported by The Women's Health Initiative Observational Study of postmenopausal women [19].
The strength and limitations of the present study require careful consideration. The study is limited by its restriction to predominantly white European men aged 60–79 years. However, the study population is socially representative and follow-up rates exceptionally high. Ascertainment of CHD death and MI is based on standard methods and both CHD mortality and MI incidence rates correspond closely with national data [32]. The ascertainment of angina is based on the presence of a clinical diagnosis, supplemented by investigations where appropriate. The validity of this approach, as indicated by its influence on future mortality and CHD incidence, has been previously demonstrated [33]. All the cases defined as angina in the present analyses were uncomplicated by the development of MI or CHD death, which would have been identified by the follow-up methods used. Moreover, only a very small proportion (~2%) were admitted to hospital with chest pain during the entire follow-up period, so it is likely that almost all these men had chronic stable angina. Potential circadian variation in the biomarkers may have influenced the associations. However, adjustment for time of blood measurement did not alter the findings.

We conclude that in older men, circulating biomarkers of inflammation and hemostasis are related to incident MI/CHD death but not to incident uncomplicated angina. These findings support the potentially important roles of inflammation and thrombotic tendency in pathogenesis of acute coronary syndromes and highlight the possible role for anti-inflammatory or anti-thrombotic therapy for those who are at high risk of MI/CHD death as indicated by their levels of inflammatory and hemostatic variables. These findings also have potential implications for prospective studies which use composite measures of CHD combining angina and MI as the endpoint when assessing the relationships between these biomarkers and CHD risk particularly in older men. Further prospective studies (and meta-analyses) are suggested to establish with greater confidence the specificity of these associations for CHD (and CVD) events associated with pathological or angiographic evidence of plaque rupture and superadded thrombosis.

Acknowledgements

The British Regional Heart Study is a Research Group funded by the British Heart Foundation.

Disclosure of Conflict of Interest

The authors state that they have no conflict of interest.

References

1 Libby P, Ridker PM, Maseri A. Inflammation and atherosclerosis. Circulation 2002; 105: 1135–43. Review.
2 Danesh J, Whincup PH, Walker M, Lennon L, Thomson A, Appleby P, Rumley A, Lowe GD. Fibrin D-dimer and coronary heart disease: prospective study and meta-analysis. Circulation 2001; 103: 2323–7.
3 Whincup P, Danesh J, Walker M, Lennon L, Thomson A, Appleby P, Rumley A, Lowe GDO. Von Willebrand factor and coronary heart disease: prospective study and meta-analysis. Eur Heart J 2002; 23: 1764–70.
4 Lowe GDO, Danesh J, Lewington S, Walker M, Lennon L, Thomson A, Rumley A, Whincup PH. Tissue plasminogen activator antigen and coronary heart disease: prospective study and meta-analysis. Eur Heart J 2004; 25: 252–9.
5 Danesh J, Wheeler JG, Hirshfeld GM, Eda S, Eriksdottir G, Rumley A, Lowe GDO, Pepys MB, Gudnason V. C-reactive protein and other circulating markers of inflammation in the prediction of coronary heart disease. N Engl J Med 2004; 350: 1387–97.
6 Fibrinogen Studies Collaboration. Plasma fibrinogen level and the risk of major cardiovascular diseases and non-vascular mortality: an individual participant meta-analysis. JAMA 2005; 294: 1799–809.
7 Danesh J, Kaptoge S, Mann AG, Sarwar N, Wood A, Angleman S, Wensley F, Higgins JPT, Lennon L, Eriksdottir G, Rumley A, Whincup PH, Lowe GDO, Gudnason V. Long-term interleukin-6 levels and subsequent risk of coronary heart disease: two new prospective studies and a systematic review. PLoS Med 2008; 5: e78.
8 Cushman M, Lemaitre RN, Kuller LH, Psaty BM, Macy EM, Sharrett R, Tracy RP. Fibrinolytic activation markers predict myocardial infarction in the elderly. The Cardiovascular Health Study. Arterioscler Thromb Vasc Biol 1999; 19: 493–8.
9 Luc G, Bard JM, Juhan Vague I, Ferrieres J, Evans A, Amouyel P, Arveiler D, Fruchart JC, Ducimetiere P. C-reactive protein, interleukin-6, and fibrinogen as predictors of coronary heart disease: the PRIME Study. Arterioscler Thromb Vasc Biol 2003; 23: 1255–61.
10 Morange PE, Simon C, Alessi MC, Luc G, Arveiler D, Ferrieres J, Amouyel P, Evans A, Ducimetiere P, Juhan-Vague I; on behalf of the Prime Study Group. Endothelial cell markers and the risk of coronary heart disease: the Prospective Epidemiological Study of Myocardial Infarction (PRIME) study. Circulation 2004; 109: 1343–8.
11 Emanu JP, Canoui-Poitirine F, Luc G, Juhan-Vague I, Morange P, Arveiler D, Ferrieres J, Amouyel P, Bingham A, Montaye M, Ruidavets JB, Haas B, Evans A, Ducimetiere P, PRIME Study Group. Contribution of novel biomarkers to incident stable angina and acute coronary syndrome: the PRIME Study. Eur Heart J 2008; 29: 1966–74.
12 Zakai NA, Katz R, Jenny NS, Psaty BM, Reiner AP, Schwartz SM, Cushman M. Inflammation and hemostasis biomarkers and cardiovascular risk in the elderly: the Cardiovascular Health Study. J Thr Thorac Haemost 2007; 5: 1128–35.
13 Tzoulaki I, Murray GD, Lee AJ, Rumley A, Lowe GDO, Fowkes GR. Relative value of inflammatory, hemostatic, and rheological factors for incident myocardial infarction and stroke: the Edinburgh Artery Study. Circulation 2007; 115: 2119–27.
14 Fuster V, Badimon L, Badimon JJ, Chesebro JH. The pathogenesis of coronary artery disease and the acute coronary syndrome. N Engl J Med 1992; 326: 242–50.
15 Itakura H, Sobel BE, Boothroyd D, Leung LL, Iribarren C, Go AS, Fortmann SP, Quertermous T, Hlatky MA; for the Atherosclerosis Disease, vascular function and genetic epidemiology (ADVANCE) Study. Do plasma biomarkers of coagulation and fibrinolysis differ between patients who have experienced an acute myocardial infarction versus stable exertional angina? Am Heart J 2007; 154: 1059–64.
16 Ford ES, Giles WH. Serum C-reactive protein and fibrinogen concentrations and self-reported angina pectoris and myocardial infarction: findings from National Health and Nutrition Examination Survey III. J Clin Epidemiol 2000; 53: 95–102.
17 Bogaty P, Poirier P, Simard S, Boyer L, Solymos S, Dagenais GR. Biological profiles in subjects with recurrent acute coronary events compared with subjects with long-standing stable angina. Circulation 2001; 103: 3062–8.

© 2009 International Society on Thrombosis and Haemostasis
18 Dunder K, Lind L, Lagerqvist B, Zethelius B, Vessby B, Lithell H. Cardiovascular risk factors for stable angina pectoris versus unheralded myocardial infarction. *Am Heart J* 2004; 147: 502–8.

19 Hsia J, Aragaki A, Bloch M, LaCroix A, Wallace R; for the WHI Investigators. Predictors of angina pectoris versus myocardial infarction from the Women’s Health Initiative Observational Study. *Am J Cardiol* 2004; 93: 673–8.

20 Dawber TR. The Framingham study. *The Epidemiology of Atherosclerotic Disease*. Cambridge, MA: Harvard University Press, 1980.

21 Hagman M, Wilhelmsen L, Wedel H, Pennert K. Risk factors for angina pectoris in a population study of Swedish men. *J Chronic Dis* 1987; 40: 179–86.

22 Shaper AG, Pocock SJ, Walker M, Cohen NM, Wale CJ, Thomson AG. British Regional Heart Study: cardiovascular risk factors in middle-aged men in 24 towns. *BMJ* 1981; 283: 179–86.

23 Wannamethee SG, Lowe GDO, Whincup PH, Rumley A, Walker M, Lennon L. Physical activity and hemostatic and inflammatory variables in elderly men. *Circulation* 2002; 105: 1785–90.

24 Emberson J, Whincup PH, Walker M, Thomas M, Alberti KGM. Biochemical measures in a population based study: the effect of fasting duration and time of day. *Ann Clin Biochem* 2002; 39: 493–501.

25 Walker M, Shaper AG, Lennon L, Whincup PH. Twenty year follow-up of a cohort study based in general practices in 24 British towns. *J Public Health Med* 2000; 22: 479–85.

26 Glyn RJ, Rosner B. Comparison of risk factors for the competing risks of coronary heart disease, stroke and venous thromboembolism. *Am J Epidemiol* 2005; 162: 975–82.

27 Ridker PM, Cannon CP, Morrow D, Rifai N, Rose LM, McCabe CH, Pfeffer MA, Braunwald E; for the Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction 22 (PROVE IT–TIMI 22) Investigators. C-reactive protein levels, outcomes after statin therapy. *N Engl J Med* 2005; 352: 20–8.

28 Pepys MB, Hirschfield GM, Tennent GA, Gallimore JR, Kahan MC, Bellotti V. Targeting C-reactive protein for the treatment of cardiovascular disease. *Nature* 2006; 440: 1217–21.

29 Eikelboom JW, Anand SS, Malmberg K, Weitz JL, Ginsberg JS, Yusuf S. Unfractionated heparin and low-molecular-weight heparin in acute coronary syndrome without ST elevation: a meta-analysis. *Lancet* 2000; 355: 1936–42.

30 Boland A, Dundar Y, Bagust A, Haycox A, Hill R, Mota RM, Walley T, Dickson R. Early thrombolysis for the treatment of acute myocardial infarction: a systematic review and economic evaluation. *Health Technol Assess* 2003; 7: 1–136.

31 Tzoulaki I, Murray GD, Price JF, Smith FB, Lee AJ, Rumley A, Lowe GD, Fowkes FG. Hemostatic factors, inflammatory markers and progressive peripheral atherosclerosis: the Edinburgh Artery Study. *Am J Epidemiol* 2006; 163: 334–41.

32 Allender S, Peto V, Scarborough P, Kaur A, Rayner M. *Coronary Heart Disease Statistics*. London: British Heart Foundation, 2008 http://www.heartstats.org.

33 Lampe FC, Whincup PH, Wannamethee SG, Shaper AG, Walker M, Ebrahim S. The natural history of prevalent ischaemic heart disease in middle-aged men. *Eur Heart J* 2000; 21: 1052–62.